You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSecobarbital
Accession NumberDB00418  (APRD00497)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionSecobarbital (marketed by Eli Lilly and Company under the brand names Seconal® and Tuinal) is a barbiturate derivative drug. It possesses anaesthetic, anticonvulsant, sedative and hypnotic properties. In the United Kingdom, it was known as Quinalbarbitone.
Structure
Thumb
Synonyms
(+-)-Secobarbital
(±)-secobarbital
5-(1-Methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-allyl-5-(1-methylbutyl)barbituric acid
5-Allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Quinalbarbitone
Secobarbitalum
Secobarbitone
Seconal
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-secobarb 100mgCapsule100 mgOralNovopharm Limited1967-12-312005-08-10Canada
Seconal Sodium Pulvule 240 0.1gmCapsule100 mgOralPharmascience Inc1939-12-312004-03-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Seconal SodiumCapsule100 mg/1OralValeant Pharmaceuticals North America LLC1983-10-03Not applicableUs
Seconal SodiumCapsule100 mg/1OralMarathon Pharmaceuticals, LLC1983-10-032016-09-30Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SeconalNot Available
Brand mixtures
NameLabellerIngredients
Tuinal Pulvule 303Pharmascience Inc
Tuinal Pulvule 304Pharmascience Inc
Salts
Name/CASStructureProperties
Secobarbital Sodium
Thumb
  • InChI Key: AXXJTNXVUHVOJW-UHFFFAOYNA-M
  • Monoisotopic Mass: 260.113687095
  • Average Mass: 260.2647
DBSALT000255
Categories
UNII1P7H87IN75
CAS number76-73-3
WeightAverage: 238.2829
Monoisotopic: 238.131742452
Chemical FormulaC12H18N2O3
InChI KeyKQPKPCNLIDLUMF-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
Pharmacology
IndicationFor the Short-term treatment of intractable insomnia for patients habituated to barbiturates
Structured Indications
PharmacodynamicsSecobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionSecobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
NMDA receptorProtein groupunknown
antagonist
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with 7-Nitroindazole.Experimental
AcebutololSecobarbital may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Secobarbital.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Secobarbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Secobarbital.Approved
AcetazolamideSecobarbital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Secobarbital.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Agomelatine.Approved, Investigational
AldesleukinSecobarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfentanil.Approved, Illicit
AliskirenSecobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Secobarbital.Approved, Investigational
AlosetronThe metabolism of Alosetron can be increased when combined with Secobarbital.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe metabolism of Alprazolam can be increased when combined with Secobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Secobarbital.Experimental
AmifostineSecobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideSecobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Secobarbital.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Secobarbital.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Secobarbital.Approved
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Secobarbital.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Secobarbital.Approved
AmlodipineSecobarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Secobarbital.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amperozide.Experimental
Amphotericin BSecobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be increased when combined with Secobarbital.Approved
AmrinoneThe metabolism of Amrinone can be increased when combined with Secobarbital.Approved
Amyl NitriteSecobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
AntipyrineThe metabolism of Antipyrine can be increased when combined with Secobarbital.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Secobarbital.Investigational
ApixabanThe metabolism of Apixaban can be increased when combined with Secobarbital.Approved
ApomorphineSecobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineSecobarbital may increase the hypotensive activities of Apraclonidine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Secobarbital.Experimental
ArformoterolThe metabolism of Arformoterol can be increased when combined with Secobarbital.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.Approved
Arsenic trioxideSecobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be increased when combined with Secobarbital.Approved
ArticaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Asenapine.Approved
AtazanavirThe metabolism of Atazanavir can be increased when combined with Secobarbital.Approved, Investigational
AtenololSecobarbital may increase the hypotensive activities of Atenolol.Approved
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Secobarbital.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Azaperone.Vet Approved
AzelastineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be increased when combined with Secobarbital.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Secobarbital.Approved
Azilsartan medoxomilSecobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Secobarbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Secobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Secobarbital.Experimental
BenazeprilSecobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Secobarbital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzocaine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be increased when combined with Secobarbital.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Secobarbital.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be increased when combined with Secobarbital.Investigational
BetaxololSecobarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.Approved
BexaroteneThe metabolism of Bexarotene can be increased when combined with Secobarbital.Approved, Investigational
BisoprololSecobarbital may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.Approved
BortezomibThe metabolism of Bortezomib can be increased when combined with Secobarbital.Approved, Investigational
BosentanThe metabolism of Bosentan can be increased when combined with Secobarbital.Approved, Investigational
BretyliumSecobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.Approved, Illicit
BromocriptineSecobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be increased when combined with Secobarbital.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Secobarbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Secobarbital.Experimental, Investigational
BumetanideSecobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Secobarbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.Approved
BuprenorphineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be increased when combined with Secobarbital.Approved
BuspironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.Approved
CabozantinibThe metabolism of Cabozantinib can be increased when combined with Secobarbital.Approved
CaffeineThe metabolism of Caffeine can be increased when combined with Secobarbital.Approved
CaiThe metabolism of Cai can be increased when combined with Secobarbital.Investigational
CanagliflozinSecobarbital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanThe metabolism of Candesartan can be increased when combined with Secobarbital.Approved
CaptoprilSecobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be increased when combined with Secobarbital.Approved, Investigational
CarbetocinSecobarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be increased when combined with Secobarbital.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.Approved
CarteololSecobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe metabolism of Carvedilol can be increased when combined with Secobarbital.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be increased when combined with Secobarbital.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Secobarbital.Approved, Investigational
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Secobarbital.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Secobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be increased when combined with Secobarbital.Approved, Vet Approved
ChlorothiazideSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Secobarbital.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneSecobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorzoxazone.Approved
CilazaprilSecobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Secobarbital.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Secobarbital.Approved
CisaprideThe metabolism of Cisapride can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clemastine.Approved
ClevidipineSecobarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clobazam.Approved, Illicit
ClofarabineSecobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Secobarbital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Secobarbital.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.Approved, Illicit
ClozapineThe metabolism of Clozapine can be increased when combined with Secobarbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Secobarbital.Approved, Illicit
ConivaptanSecobarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Secobarbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Secobarbital.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyproheptadine.Approved
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Secobarbital.Approved
DantroleneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be increased when combined with Secobarbital.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Secobarbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be increased when combined with Secobarbital.Approved, Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Secobarbital.Experimental
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Secobarbital.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Secobarbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Secobarbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Secobarbital.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dezocine.Approved
DiazepamThe metabolism of Diazepam can be increased when combined with Secobarbital.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be increased when combined with Secobarbital.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Secobarbital.Approved, Vet Approved
DiclofenamideSecobarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Secobarbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Secobarbital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Secobarbital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Secobarbital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be increased when combined with Secobarbital.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.Approved
DinutuximabSecobarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be increased when combined with Secobarbital.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate.Approved, Illicit
DipyridamoleSecobarbital may increase the hypotensive activities of Dipyridamole.Approved
DolasetronThe metabolism of Dolasetron can be increased when combined with Secobarbital.Approved
DomperidoneThe metabolism of Domperidone can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be increased when combined with Secobarbital.Approved
DopamineThe metabolism of Dopamine can be increased when combined with Secobarbital.Approved
DoramectinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Secobarbital.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Secobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Secobarbital.Investigational
DoxazosinSecobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Secobarbital.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Secobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Secobarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Secobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Secobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Secobarbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Secobarbital.Approved
EletriptanThe metabolism of Eletriptan can be increased when combined with Secobarbital.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Secobarbital.Approved
EmpagliflozinSecobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilSecobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSecobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Secobarbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.Approved
EperisoneThe metabolism of Eperisone can be increased when combined with Secobarbital.Approved, Investigational
EplerenoneSecobarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Secobarbital.Approved
EprosartanSecobarbital may increase the hypotensive activities of Eprosartan.Approved
ErlotinibThe metabolism of Erlotinib can be increased when combined with Secobarbital.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Secobarbital.Investigational
EsmololSecobarbital may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Estazolam.Approved, Illicit
EstradiolThe metabolism of Estradiol can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Secobarbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Secobarbital.Approved
EstroneThe metabolism of Estrone can be increased when combined with Secobarbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Secobarbital.Approved
EszopicloneThe metabolism of Eszopiclone can be increased when combined with Secobarbital.Approved
Etacrynic acidSecobarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Secobarbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Secobarbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Secobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etizolam.Approved
EtodolacThe metabolism of Etodolac can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Secobarbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Secobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Secobarbital.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be increased when combined with Secobarbital.Approved
EzogabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.Approved
FelodipineSecobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Secobarbital.Withdrawn
FenoldopamSecobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fexofenadine.Approved
FimasartanSecobarbital may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Secobarbital.Investigational
FlunarizineThe metabolism of Flunarizine can be increased when combined with Secobarbital.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be increased when combined with Secobarbital.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Secobarbital.Approved
FluoxetineThe metabolism of Fluoxetine can be increased when combined with Secobarbital.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Secobarbital.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Secobarbital.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Secobarbital.Approved, Investigational
FormoterolThe metabolism of Formoterol can be increased when combined with Secobarbital.Approved, Investigational
FosinoprilSecobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Fosphenytoin can be increased when combined with Secobarbital.Approved
FospropofolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fospropofol.Approved, Illicit
FurosemideSecobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Secobarbital is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Secobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GavestinelThe metabolism of Gavestinel can be increased when combined with Secobarbital.Investigational
GepironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Secobarbital.Approved
GliclazideThe metabolism of Gliclazide can be increased when combined with Secobarbital.Approved
GlimepirideThe metabolism of Glimepiride can be increased when combined with Secobarbital.Approved
GlipizideThe metabolism of Glipizide can be increased when combined with Secobarbital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be increased when combined with Secobarbital.Approved
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Secobarbital.Approved, Vet Approved
GuanfacineThe metabolism of Guanfacine can be increased when combined with Secobarbital.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be increased when combined with Secobarbital.Approved
HaloperidolThe metabolism of Haloperidol can be increased when combined with Secobarbital.Approved
HalothaneThe metabolism of Halothane can be increased when combined with Secobarbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Secobarbital.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Secobarbital.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Secobarbital.Approved
HydralazineSecobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideSecobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be increased when combined with Secobarbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Secobarbital.Approved
IdarubicinThe metabolism of Idarubicin can be increased when combined with Secobarbital.Approved
IfosfamideThe metabolism of Ifosfamide can be increased when combined with Secobarbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.Approved
IloprostSecobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Imatinib can be increased when combined with Secobarbital.Approved
ImidaprilSecobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Secobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideSecobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Secobarbital.Withdrawn
indisulamThe metabolism of indisulam can be increased when combined with Secobarbital.Investigational
IndomethacinThe metabolism of Indomethacin can be increased when combined with Secobarbital.Approved, Investigational
IndoraminSecobarbital may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanThe metabolism of Irbesartan can be increased when combined with Secobarbital.Approved, Investigational
IsocarboxazidSecobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineSecobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineSecobarbital may increase the hypotensive activities of Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be increased when combined with Secobarbital.Approved
KetamineThe metabolism of Ketamine can be increased when combined with Secobarbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketazolam.Approved
KetobemidoneThe metabolism of Ketobemidone can be increased when combined with Secobarbital.Approved
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Secobarbital.Approved, Vet Approved
LabetalolSecobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Secobarbital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Secobarbital.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be increased when combined with Secobarbital.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be increased when combined with Secobarbital.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Secobarbital.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be increased when combined with Secobarbital.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levetiracetam.Approved, Investigational
LevobunololSecobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be increased when combined with Secobarbital.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Secobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol.Approved
LevosimendanSecobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be increased when combined with Secobarbital.Investigational
LidocaineThe metabolism of Lidocaine can be increased when combined with Secobarbital.Approved, Vet Approved
LisinoprilSecobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lofentanil.Illicit
LofexidineSecobarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be increased when combined with Secobarbital.Approved
LoratadineThe metabolism of Loratadine can be increased when combined with Secobarbital.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.Approved
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Secobarbital.Approved
LosartanThe metabolism of Losartan can be increased when combined with Secobarbital.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Secobarbital is combined with Lu AA21004.Investigational
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Secobarbital.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Secobarbital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Secobarbital.Approved
MannitolSecobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.Approved
MecamylamineSecobarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Secobarbital.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Secobarbital.Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Secobarbital.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be increased when combined with Secobarbital.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Melperone.Approved
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Secobarbital.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.Approved
MestranolThe metabolism of Mestranol can be increased when combined with Secobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.Approved
MethadoneThe metabolism of Methadone can be increased when combined with Secobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Secobarbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideSecobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methohexital.Approved
MethotrimeprazineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be increased when combined with Secobarbital.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.Approved
MethyclothiazideSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaSecobarbital may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylphenobarbital.Approved
MetipranololSecobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneSecobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololSecobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Secobarbital.Approved
MetyrosineSecobarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Secobarbital.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Secobarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Investigational
MinoxidilSecobarbital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Moclobemide can be increased when combined with Secobarbital.Approved
MoexiprilSecobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Molindone.Approved
MontelukastThe metabolism of Montelukast can be increased when combined with Secobarbital.Approved
MorphineThe metabolism of Morphine can be increased when combined with Secobarbital.Approved, Investigational
MoxonidineSecobarbital may increase the hypotensive activities of Moxonidine.Approved
muraglitazarThe metabolism of muraglitazar can be increased when combined with Secobarbital.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Investigational
NadololSecobarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Secobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine.Approved
NaloxoneThe metabolism of Naloxone can be increased when combined with Secobarbital.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be increased when combined with Secobarbital.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be increased when combined with Secobarbital.Approved, Investigational
NebivololSecobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nefazodone.Approved, Withdrawn
NesiritideSecobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be increased when combined with Secobarbital.Approved
NevirapineThe metabolism of Nevirapine can be increased when combined with Secobarbital.Approved
NicardipineThe metabolism of Nicardipine can be increased when combined with Secobarbital.Approved
NiclosamideThe metabolism of Niclosamide can be increased when combined with Secobarbital.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be increased when combined with Secobarbital.Approved
NifedipineSecobarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Secobarbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Secobarbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Secobarbital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Secobarbital.Approved, Withdrawn
NimodipineSecobarbital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineSecobarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Secobarbital.Approved
Nitric OxideSecobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinSecobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideSecobarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Secobarbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Secobarbital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Secobarbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Secobarbital.Approved
ObinutuzumabSecobarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Secobarbital.Approved, Investigational
OlmesartanSecobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be increased when combined with Secobarbital.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Secobarbital.Approved
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be increased when combined with Secobarbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Secobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Opium.Approved, Illicit
OrphenadrineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be increased when combined with Secobarbital.Approved
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Secobarbital.Approved
OxazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.Approved
PapaverineSecobarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Secobarbital.Approved
ParecoxibThe metabolism of Parecoxib can be increased when combined with Secobarbital.Approved
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Secobarbital.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be increased when combined with Secobarbital.Approved
PenbutololSecobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be increased when combined with Secobarbital.Approved
PentazocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Secobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Secobarbital.Approved
PerindoprilSecobarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be increased when combined with Secobarbital.Approved
PethidineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be increased when combined with Secobarbital.Withdrawn
PhenelzineSecobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Secobarbital.Approved
PhenobarbitalThe metabolism of Phenobarbital can be increased when combined with Secobarbital.Approved
PhenoxybenzamineSecobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Secobarbital.Approved
PhentolamineSecobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Secobarbital.Approved, Vet Approved
PhenytoinThe metabolism of Phenytoin can be increased when combined with Secobarbital.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pimozide.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Secobarbital.Approved
PindololSecobarbital may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Secobarbital.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Piritramide.Investigational
PiroxicamThe metabolism of Piroxicam can be increased when combined with Secobarbital.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Secobarbital.Approved
PizotifenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pizotifen.Approved
PolythiazideSecobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be increased when combined with Secobarbital.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.Approved
PramipexoleSecobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pramocaine.Approved
PrasugrelThe metabolism of Prasugrel can be increased when combined with Secobarbital.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Secobarbital.Approved
PrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam.Approved, Illicit
PrazosinSecobarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Secobarbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Secobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Secobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be increased when combined with Secobarbital.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be increased when combined with Secobarbital.Approved
PromazineThe metabolism of Promazine can be increased when combined with Secobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Secobarbital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propoxycaine.Approved
PropranololSecobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Secobarbital.Approved
PSD502The risk or severity of adverse effects can be increased when Secobarbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Secobarbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe metabolism of Quazepam can be increased when combined with Secobarbital.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quetiapine.Approved
QuinaprilSecobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneSecobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinidineThe metabolism of Quinidine can be increased when combined with Secobarbital.Approved
QuinineThe metabolism of Quinine can be increased when combined with Secobarbital.Approved
RacloprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon.Approved, Investigational
RamiprilSecobarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineSecobarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Secobarbital.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be increased when combined with Secobarbital.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Secobarbital.Approved
RifabutinThe metabolism of Secobarbital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Rifampicin can be increased when combined with Secobarbital.Approved
RifapentineThe metabolism of Secobarbital can be increased when combined with Rifapentine.Approved
RiociguatThe metabolism of Riociguat can be increased when combined with Secobarbital.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Secobarbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Secobarbital.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Secobarbital.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Romifidine.Vet Approved
RopiniroleSecobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Secobarbital.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Secobarbital.Approved
RotigotineSecobarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Secobarbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Secobarbital is combined with S-Ethylisothiourea.Experimental
SacubitrilSecobarbital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Secobarbital is combined with Sage 547.Investigational
Salicylic acidThe metabolism of Salicylic acid can be increased when combined with Secobarbital.Approved, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.Approved
SelegilineThe metabolism of Selegiline can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be increased when combined with Secobarbital.Approved
SeratrodastThe metabolism of Seratrodast can be increased when combined with Secobarbital.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be increased when combined with Secobarbital.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be increased when combined with Secobarbital.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be increased when combined with Secobarbital.Approved
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Secobarbital.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
Sodium NitriteSecobarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Secobarbital.Approved
SorafenibThe metabolism of Sorafenib can be increased when combined with Secobarbital.Approved, Investigational
SotalolSecobarbital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneSecobarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Stiripentol.Approved
StreptokinaseSecobarbital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Secobarbital.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Secobarbital.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Secobarbital.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Secobarbital.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Secobarbital.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Secobarbital.Approved
SuprofenThe metabolism of Suprofen can be increased when combined with Secobarbital.Approved, Withdrawn
SuvorexantSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Secobarbital.Approved
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Secobarbital.Approved
TamsulosinSecobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tasimelteon.Approved
TazaroteneThe metabolism of Tazarotene can be increased when combined with Secobarbital.Approved, Investigational
TelmisartanSecobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be increased when combined with Secobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Secobarbital.Approved
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Secobarbital.Approved
TerazosinSecobarbital may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be increased when combined with Secobarbital.Withdrawn
TestosteroneThe metabolism of Testosterone can be increased when combined with Secobarbital.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrodotoxin.Investigational
ThalidomideSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be increased when combined with Secobarbital.Approved
ThiamylalThe metabolism of Thiamylal can be increased when combined with Secobarbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Secobarbital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiletamine.Vet Approved
TimololSecobarbital may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tizanidine.Approved
TolazolineSecobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Secobarbital.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.Approved
TolterodineThe metabolism of Tolterodine can be increased when combined with Secobarbital.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Topiramate.Approved
TorasemideThe metabolism of Torasemide can be increased when combined with Secobarbital.Approved
TrabectedinThe metabolism of Trabectedin can be increased when combined with Secobarbital.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.Approved, Investigational
TrandolaprilSecobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Secobarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be increased when combined with Secobarbital.Approved, Investigational, Nutraceutical
TriamtereneSecobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triazolam.Approved
TrichlormethiazideSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Secobarbital.Approved
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Secobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Secobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Secobarbital.Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Secobarbital is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Secobarbital.Approved
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Secobarbital.Investigational, Withdrawn
Valproic AcidThe serum concentration of Secobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Valsartan can be increased when combined with Secobarbital.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Secobarbital.Approved
VerapamilThe metabolism of Verapamil can be increased when combined with Secobarbital.Approved
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Secobarbital.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Secobarbital.Investigational
VismodegibThe metabolism of Vismodegib can be increased when combined with Secobarbital.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Secobarbital.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be increased when combined with Secobarbital.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Secobarbital.Approved
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Secobarbital.Approved
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Secobarbital.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Secobarbital.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Secobarbital.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be increased when combined with Secobarbital.Approved
ZileutonThe metabolism of Zileuton can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolazepam.Vet Approved
ZolpidemSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe metabolism of Zopiclone can be increased when combined with Secobarbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9331
Blood Brain Barrier+0.9762
Caco-2 permeable-0.5792
P-glycoprotein substrateSubstrate0.6367
P-glycoprotein inhibitor INon-inhibitor0.5256
P-glycoprotein inhibitor IINon-inhibitor0.9756
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7863
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.736
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.7679
CYP450 2D6 inhibitorNon-inhibitor0.9276
CYP450 2C19 inhibitorNon-inhibitor0.7353
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9176
Ames testNon AMES toxic0.6131
CarcinogenicityNon-carcinogens0.8977
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity3.0894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9603
hERG inhibition (predictor II)Non-inhibitor0.9471
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Anabolic inc
  • Barr laboratories inc
  • Everylife
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Kv pharmaceutical co
  • Lannett co inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Purepac pharmaceutical co
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Wyeth ayerst laboratories
  • Ranbaxy pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral
Prices
Unit descriptionCostUnit
Seconal 100 mg capsule5.23USD capsule
Seconal sodium 100 mg capsule4.91USD capsule
Seconal sodium 100 mg pulvul0.93USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100 °CPhysProp
water solubility550 mg/LNot Available
logP1.97HANSCH,C ET AL. (1995)
pKa7.8WOLLWEBER,H (1989)
Predicted Properties
PropertyValueSource
Water Solubility1.21 mg/mLALOGPS
logP2.2ALOGPS
logP2.03ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity62.65 m3·mol-1ChemAxon
Polarizability24.33 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.04 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014i-6900000000-eb3ae85faebb012ef83bView in MoNA
1D NMR1H NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Peters JA, Kirkness EF, Callachan H, Lambert JJ, Turner AJ: Modulation of the GABAA receptor by depressant barbiturates and pregnane steroids. Br J Pharmacol. 1988 Aug;94(4):1257-69. [PubMed:2850060 ]
  6. Miller LG, Deutsch SI, Greenblatt DJ, Paul SM, Shader RI: Acute barbiturate administration increases benzodiazepine receptor binding in vivo. Psychopharmacology (Berl). 1988;96(3):385-90. [PubMed:2906155 ]
  7. Kirkness EF, Turner AJ: The gamma-aminobutyrate/benzodiazepine receptor from pig brain. Purification and characterization of the receptor complex from cerebral cortex and cerebellum. Biochem J. 1986 Jan 1;233(1):265-70. [PubMed:3006661 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  9. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  10. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N: Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab Dispos. 1999 Mar;27(3):379-84. [PubMed:10064569 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23